Metagenomi Therapeutics, Inc. (MGX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the MGX-001 program and business update conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. I would now like to hand the conference over to your speaker today. Steven Jasper, Managing Director at Gilmartin Group. Ladies and gentlemen, welcome to the Metagenomic Conference Call to discuss the company's MGX-001 program and business updates. Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our most recent Form 10-K and 10-Q on file with the SEC for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. Joining us on the call today with prepared remarks are the company's newly appointed Chief Executive Officer, Giann Irish, and the company's Senior Vice President of Research, Alan Brooks. Also joining on the call today is Dr. Glenn Pierce. an internationally recognized hemophilia physician-scientist. After the company's prepared remarks, we will open the line for a live Q&A session. I would now like to hand the call over to John Irish. John, please go ahead. Welcome to today's update, our wholly-owned MGX-001 Hemophilia A program, and thank you for joining us. I'm extremely excited to share new data today from the recent dose range finding s...